Matches in Wikidata for { <http://www.wikidata.org/entity/Q91681526> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q91681526 description "article scientifique publié en 2019" @default.
- Q91681526 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q91681526 description "scientific article published on 01 July 2019" @default.
- Q91681526 description "wetenschappelijk artikel" @default.
- Q91681526 description "наукова стаття, опублікована 1 липня 2019" @default.
- Q91681526 name "Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'" @default.
- Q91681526 name "Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'" @default.
- Q91681526 type Item @default.
- Q91681526 label "Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'" @default.
- Q91681526 label "Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'" @default.
- Q91681526 prefLabel "Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'" @default.
- Q91681526 prefLabel "Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'" @default.
- Q91681526 P1433 Q91681526-ACA5F405-C2A2-42F5-9D86-D091FF0A61B9 @default.
- Q91681526 P1476 Q91681526-54574219-2388-4E59-B7EB-FE5D7253EBB9 @default.
- Q91681526 P2093 Q91681526-2336F2C5-E24F-45A8-A3B8-BAB50FFCF673 @default.
- Q91681526 P2093 Q91681526-B1C7E1D7-7D58-4338-94AF-1CFB1BAAAD8E @default.
- Q91681526 P304 Q91681526-F4F859B7-21D3-4DCB-9944-46BBA84AFD15 @default.
- Q91681526 P31 Q91681526-A8D9135E-4A2A-461D-96AD-835C5353E6D4 @default.
- Q91681526 P356 Q91681526-02F265B0-6BC0-4D45-9309-857D7BE9E6B1 @default.
- Q91681526 P433 Q91681526-F673C28B-0E50-40AC-94E6-ACCAD05EA0ED @default.
- Q91681526 P478 Q91681526-2C8364EA-71E0-4B4D-8651-DDE066A7162E @default.
- Q91681526 P50 Q91681526-408C814A-8ACF-46DF-9F7E-DB4892958315 @default.
- Q91681526 P577 Q91681526-99480CB8-8448-44EA-B937-D7CE20D350D7 @default.
- Q91681526 P698 Q91681526-5D7CC7F8-C25B-4CDA-A46B-A17B43FEEA1D @default.
- Q91681526 P921 Q91681526-AD3160D1-0656-4352-9A54-EA51FF52480E @default.
- Q91681526 P921 Q91681526-E416805B-DA8A-4378-A930-47A6CE24AE12 @default.
- Q91681526 P356 S40273-019-00803-7 @default.
- Q91681526 P698 31044349 @default.
- Q91681526 P1433 Q7180778 @default.
- Q91681526 P1476 "Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'" @default.
- Q91681526 P2093 "Lydia Walder" @default.
- Q91681526 P2093 "Mark Fisher" @default.
- Q91681526 P304 "965-967" @default.
- Q91681526 P31 Q13442814 @default.
- Q91681526 P356 "10.1007/S40273-019-00803-7" @default.
- Q91681526 P433 "7" @default.
- Q91681526 P478 "37" @default.
- Q91681526 P50 Q91681517 @default.
- Q91681526 P577 "2019-07-01T00:00:00Z" @default.
- Q91681526 P698 "31044349" @default.
- Q91681526 P921 Q172341 @default.
- Q91681526 P921 Q7083106 @default.